Hepatoma-derived growth factor promotes the resistance to anti-tumor effects of nordihydroguaiaretic acid in colorectal cancer cells

European Journal of Pharmacology

Volumn 645, Issue 1-3, 2010, Pages 55-62

  Liao, Fei ^a   Liu, Meng ^a   Lv, Li ^b   Dong, Weiguo ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Renmin Hospital of Huiyang   (China)

Author keywords

Apoptosis; Chemotherapy resistance; Colorectal carcinoma; Hepatoma derived growth factor; Nordihydroguairetic acid

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; GLYCOPROTEIN P; HEPATOMA DERIVED GROWTH FACTOR; NORDIHYDROGUAIARETIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL SURVIVAL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOCHROMES C; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NORDIHYDROGUAIARETIC ACID; P-GLYCOPROTEIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 77956181405     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.07.033     Document Type: Article

References (29)

1. Ansar S., Iqbal M., Athar M. Nordihydroguairetic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity, and renal tumour promotion, in mice. Carcinogenesis 1999, 20:599-606.
2. Azambuja E., Durbecq V., Rosa D.D., Colozza M., Larsimont D., Piccart-Gebhart M., Cardoso F. HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Annals of Oncology 2008, 19:223-232.
3. Boatright K., Salvesen G. Mechanisms of caspase activation. Current Opinion in Cell Biology 2003, 15:725-731.
4. Costa S., Paillaud E., Fages C., Rochette-Egly C., Plassat J., Jouault H., Perzelova A., Tardy M. Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation. European Journal of Cancer 2001, 37:520-530.
5. Ding X., Kuszynski C., El-Metwally T., Adrian T. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochemical and Biophysical Research Communications 1999, 266:392-399.
6. Fulda S., Debatin K. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
7. Galluzzi L., Larochette N., Zamzami N., Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
8. Gonda K., Tsuchiya H., Sakabe T., Akechi Y., Ikeda R., Nishio R., Terabayashi K., Ishii K., Matsumi Y., Ashla A. Synthetic retinoid CD437 induces mitochondria-mediated apoptosis in hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications 2008, 370:629-633.
9. Hausott B., Greger H., Marian B. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. Journal of Cancer Research and Clinical Oncology 2003, 129:569-576.
10. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., Bodmer J., Schneider P., Seed B., Tschopp J. Fas triggers an alternative, caspase-8 - independent cell death pathway using the kinase RIP as effector molecule. Nature Immunology 2000, 1:489-495.
11. Iwasaki T., Nakagawa K., Nakamura H., Takada Y., Matsui K., Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncology Reports 2005, 13:1075-1080.
12. Kasukabe T., Okabe-Kado J., Kato N., Sassa T., Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Research 2005, 7:1097-1110.
13. Lee C., Jang Y., Her S., Moon Y., Baek S., Eling T. Nordihydroguaiaretic acid, an antioxidant, inhibits transforming growth factor-β activity through the inhibition of Smad signaling pathway. Experimental Cell Research 2003, 289:335-341.
14. Li P., Nijhawan D., Budihardjo I., Srinivasula S., Ahmad M., Alnemri E., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-490.
15. Mao J., Xu Z., Fang Y., Wang H., Xu J., Ye J., Zheng S., Zhu Y. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Science 2008, 99:2120-2127.
16. Moody T., Leyton J., Martinez A., Hong S., Malkinson A., Mulshine J. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Experimental Lung Research 1998, 24:617-628.
17. Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., Gallo D., Martinelli E., Ranelletti F.O., Ferrandina G., Scambia G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clinical Cancer Research 2005, 11:298-305.
18. Nakamura H., Kambe H., Egawa T., Kimura Y., Ito H., Hayashi E., Yamamoto H., Sato J., Kishimoto S. Partial purification and characterization of human hepatoma-derived growth factor. Clinica Chimica Acta; International Journal of Clinical Chemistry 1989, 183:273-284.
19. Noda I., Fujieda S., Seki M., Tanaka N., Sunaga H., Ohtsubo T., Tsuzuki H., Fan G.K., Saito H. Inhibition of N-linked glycosylation by tunicamycin enhances sensitivity to cisplatin in human head-and-neck carcinoma cells. International Journal of Cancer 1999, 80:279-284.
20. Okuda Y., Nakamura H., Yoshida K., Enomoto H., Uyama H., Hirotani T., Funamoto M., Ito H., Everett A., Hada T. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Science 2003, 94:1034-1041.
21. Oyama K., Shiota G., Ito H., Murawaki Y., Kawasaki H. Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis 2002, 23:885-892.
22. Parkin D., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005, 55:74-108.
23. Slee E., Harte M., Kluck R., Wolf B., Casiano C., Newmeyer D., Wang H., Reed J., Nicholson D., Alnemri E. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. The Journal of Cell Biology 1999, 144:281-292.
24. Tong W., Ding X., Witt R., Adrian T. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Molecular Cancer Therapeutics 2002, 1:929-935.
25. Trang T., Sutak M., Quirion R., Jhamandas K. Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal. British Journal of Pharmacology 2003, 140:295-304.
26. Tsang T., Tang W., Tsang W., Co N., Kong S., Kwok T. Downregulation of hepatoma-derived growth factor activates the Bad-mediated apoptotic pathway in human cancer cells. Apoptosis 2008, 13:1135-1147.
27. Yamamoto S., Tomita Y., Hoshida Y., Takiguchi S., Fujiwara Y., Yasuda T., Doki Y., Yoshida K., Aozasa K., Nakamura H. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clinical Cancer Research 2006, 12:117-122.
28. Yang J., Liu X., Bhalla K., Kim C., Ibrado A., Cai J., Peng T., Jones D., Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997, 275:1129.
29. Zhang J., Ren H., Yuan P., Lang W., Zhang L., Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Research 2006, 66:18-23.